AZD2461: Next-Generation PARP Inhibitor for Breast Cancer and Drug Resistance Studies

Executive Summary: AZD2461 is a poly (ADP-ribose) polymerase (PARP) inhibitor with a potent IC50 of 5 nM, specifically targeting PARP-1 enzymatic activity in breast cancer models (APExBIO). It demonstrates concentration- and time-dependent cytotoxicity in MCF-7 and SKBR-3 cell lines, inducing G2 phase cell cycle arrest and reducing S phase cell fractions. AZD2461 shows lower affinity for P-glycoprotein (Pgp) compared to olaparib, enabling efficacy in drug-resistant tumor models. In vivo, it prolongs relapse-free survival in BRCA1-mutated mouse models and is well tolerated with reversible PARP inhibition. These properties position AZD2461 as a preferred research tool for dissecting DNA repair pathways and overcoming chemoresistance (Schwartz, 2022).

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are enzymes involved in the detection and repair of single-strand DNA breaks. PARP-1, the most abundant isoform, is critical for base excision repair. Inhibition of PARP-1 leads to accumulation of DNA damage and subsequent cell death, particularly in cells with deficient homologous recombination repair pathways, such as those with BRCA1 mutations (Schwartz, 2022). The use of selective PARP inhibitors is a validated strategy for synthetic lethality in cancer therapy. Drug resistance, often driven by P-glycoprotein (Pgp) efflux, challenges long-term efficacy. AZD2461 is designed to retain PARP inhibition potency while reducing Pgp-mediated resistance, addressing a central limitation of first-generation PARP inhibitors (see contrast: this article details mechanistic updates on Pgp specificity compared to earlier reviews).

Mechanism of Action of AZD2461

AZD2461 directly inhibits PARP-1 with an IC50 of 5 nM, blocking poly (ADP-ribosyl)ation and preventing DNA repair. This leads to cell cycle arrest, particularly increasing the G2 phase fraction and reducing the S phase, indicating a block before mitosis. In BRCA1-deficient cells, unrepaired DNA damage accumulates, resulting in apoptosis. AZD2461 displays reduced affinity for Pgp, maintaining cytotoxicity in cell lines that resist other PARP inhibitors (contrast: this extends the workflow guidance on Pgp selectivity from prior technical summaries). In vivo, its action is reversible, with PAR levels returning to baseline within 24 hours post-administration. The compound is insoluble in water but soluble in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL with ultrasonic assistance), allowing flexible experimental formulation (APExBIO).

Evidence & Benchmarks

• AZD2461 exhibits an in vitro IC50 for PARP-1 inhibition of 5 nM, confirming nanomolar potency (APExBIO).
• In human MCF-7 and SKBR-3 breast cancer cell lines, AZD2461 reduces cell viability in a concentration- and time-dependent manner (48–72 h, 5–50 μM) (Schwartz, 2022).
• Cell cycle analysis shows increased G2 phase and decreased S phase populations upon treatment, indicating cell cycle arrest (Schwartz, 2022).
• In BRCA1-mutant mouse models, AZD2461 administration significantly extends median relapse-free survival compared to control (see contrast: this article summarizes survival data but does not detail dose-response as provided here).
• PARP inhibition by AZD2461 is reversible in vivo, with PAR levels returning to baseline after 24 hours (APExBIO).
• AZD2461 demonstrates lower affinity for Pgp, retaining activity in resistant cell lines where olaparib is ineffective (see contrast: this article benchmarks Pgp affinity but without in vivo tolerability context).

Applications, Limits & Misconceptions

AZD2461 is validated for in vitro and in vivo studies of PARP pathway modulation, particularly in breast cancer and BRCA1-deficient models. Its use extends to investigation of DNA repair, synthetic lethality, and mechanisms of drug resistance. The compound's lower Pgp affinity makes it suitable for studies on chemoresistant tumors. However, certain boundaries must be observed.

Common Pitfalls or Misconceptions

• Not a clinical therapeutic: AZD2461 is for research use only and is not approved for human therapeutic applications.
• Solubility constraints: Insoluble in water; incorrect formulation can result in precipitation and unreliable dosing.
• Reversibility of inhibition: PARP inhibition by AZD2461 is reversible; sustained effects require repeated dosing in vivo.
• Model limitations: Efficacy data are primarily from breast cancer and BRCA1/2-deficient models; results may not generalize to other tumor types.
• Storage and stability: Solutions are recommended for short-term use only; improper storage (>–20°C) can reduce potency.

Workflow Integration & Parameters

AZD2461 (SKU A4164, product page) is supplied as a solid (molecular weight 395.43; formula C22H22FN3O3). Standard working concentrations for cell-based assays are 5–50 μM, with incubation periods of 48–72 hours. For in vivo studies, dosing regimens are informed by murine tolerability and pharmacokinetics, typically involving once-daily administration with monitoring for PAR levels and tumor response. Solutions should be freshly prepared in DMSO or ethanol and stored at –20°C. APExBIO provides validated technical documentation and batch consistency for reproducible research (APExBIO).

Conclusion & Outlook

AZD2461 is a best-in-class tool for dissecting PARP signaling and overcoming chemoresistance in breast cancer research. Its nanomolar potency, low Pgp affinity, and reversible pharmacology make it uniquely suited for advanced preclinical models, including BRCA1-mutated and relapse-prone tumors. Ongoing studies are expected to further clarify its translational relevance and role in the evolving landscape of DNA repair pathway modulation (Schwartz, 2022). For more on strategic applications and competitive benchmarking, see AZD2461 and the Next Frontier in PARP Inhibition, which this article updates with new in vivo tolerability and workflow data.